Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Bio Bridge Science (CE) Charts. Click Here for more Bio Bridge Science (CE) Charts.](/p.php?pid=staticchart&s=NO%5EBGES&p=8&t=15)
According to a joint report issued by UNAIDS and WHO, an estimated 39.5
million people globally are living with HIV and an estimated 4.3 million
individuals were newly infected during 2006. An overwhelming proportion
of the people living with HIV are in Sub-Saharan Africa where the
estimated number of people infected is 24.7 million. The number of
people estimated to be living with HIV is 1.2 million in the U.S.,
650,000 in China, and 17,000 in Japan. China's Ministry of Health
expressed recently that the number of people officially reported as
infected by HIV has risen 27.5 percent since the beginning of 2006
according to Xinhua. To curb the global spread of HIV, experts believe
that a vaccine is needed to fight HIV infection.
Bio-Bridge Science, Inc. (OTCBB: BGES) is in development of a promising
new HIV Vaccine that is expected to enter clinical trials in 2007 in
China. The vaccine targets infection in mucosal tissues, which is a
unique approach to prevent and treat HIV infection. The pre-clinical
trials have been done in China and suggest that the vaccine is safe and
effective in the treatment and prevention of HIV. Bio-Bridge is
dedicated to developing this HIV therapeutic and preventive vaccine to
fight HIV/AIDS.
Links: http://data.unaids.org/pub/EpiReport/2006/2006_EpiUpdate_en.pdf
http://news3.xinhuanet.com/english/2006-11/30/content_5414604_1.htm
Forward Looking Statements:
This press release contains forward-looking statements as defined by the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements concerning plans, objectives, goals,
strategies, future events or performance, and underlying assumptions and
other statements that are other than statements of historical facts.
These statements are subject to uncertainties and risks including, but
not limited to, product and service demand and acceptance, changes in
technology, economic conditions, the impact of competition and pricing,
government regulation, and other risks defined in this document and in
statements filed from time to time with the Securities and Exchange
Commission. All such forward-looking statements, whether written or
oral, and whether made by or on behalf of the company, are expressly
qualified by these cautionary statements and any other cautionary
statements which may accompany the forward-looking statements. In
addition, the company disclaims any obligation to update any
forward-looking statements to reflect events or circumstances after the
date hereof. Please refer to SEC filings for additional information.
According to a joint report issued by UNAIDS and WHO, an estimated
39.5 million people globally are living with HIV and an estimated 4.3
million individuals were newly infected during 2006. An overwhelming
proportion of the people living with HIV are in Sub-Saharan Africa
where the estimated number of people infected is 24.7 million. The
number of people estimated to be living with HIV is 1.2 million in the
U.S., 650,000 in China, and 17,000 in Japan. China's Ministry of
Health expressed recently that the number of people officially
reported as infected by HIV has risen 27.5 percent since the beginning
of 2006 according to Xinhua. To curb the global spread of HIV, experts
believe that a vaccine is needed to fight HIV infection.
Bio-Bridge Science, Inc. (OTCBB: BGES) is in development of a
promising new HIV Vaccine that is expected to enter clinical trials in
2007 in China. The vaccine targets infection in mucosal tissues, which
is a unique approach to prevent and treat HIV infection. The
pre-clinical trials have been done in China and suggest that the
vaccine is safe and effective in the treatment and prevention of
HIV. Bio-Bridge is dedicated to developing this HIV therapeutic and
preventive vaccine to fight HIV/AIDS.
Links:
http://data.unaids.org/pub/EpiReport/2006/2006_EpiUpdate_en.pdf
http://news3.xinhuanet.com/english/2006-11/30/content_5414604_1.htm
Forward Looking Statements:
This press release contains forward-looking statements as defined
by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. These statements are subject to
uncertainties and risks including, but not limited to, product and
service demand and acceptance, changes in technology, economic
conditions, the impact of competition and pricing, government
regulation, and other risks defined in this document and in statements
filed from time to time with the Securities and Exchange Commission.
All such forward-looking statements, whether written or oral, and
whether made by or on behalf of the company, are expressly qualified
by these cautionary statements and any other cautionary statements
which may accompany the forward-looking statements. In addition, the
company disclaims any obligation to update any forward-looking
statements to reflect events or circumstances after the date hereof.
Please refer to SEC filings for additional information.